BioNTech SE (NASDAQ:BNTX), a biotechnology company renowned for its mRNA technology platform and COVID-19 vaccine success, is navigating a crucial phase in its evolution. With a market capitalization ...

In a report released today, Jessica Fye from J.P. Morgan maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.

Investors in BioNTech SE (Symbol: BNTX) saw new options begin trading this week, for the September 19th expiration. One of the key data points that goes into the price an option buyer is willing ...

PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the ...

Check Out Our Latest Stock Report on BNTX BioNTech Trading Down 3.3 % NASDAQ:BNTX opened at $118.14 on Friday. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ...

Healthcare and vaccine stocks are likely to be in the spotlight on Wednesday as Robert F. Kennedy Jr., U.S. President Donald Trump's pick to run the Department of Health and Human Services, is due to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Leading vaccine makers are under investor scrutiny as Robert F. Kennedy Jr., a notable vaccine skeptic and President Donald Trump’s nominee to lead the Department of Health and Human Services (HHS), ...

After hours: 7:46:26 p.m. EST ...